Akeso's Ivonescimab Gains Prominence in FirstWord Pharma's 2026 Forecast
Event summary
- Akeso's ivonescimab, a PD-1/VEGF bispecific antibody, has been included in FirstWord Pharma's 'The Drugs That Will Shape 2026' list.
- Ivonescimab is the only drug on the list originating from independent R&D of a Chinese pharmaceutical company.
- The list features other prominent therapies from companies like Eli Lilly, AstraZeneca, Novartis, and Moderna/Merck.
- Akeso has over 50 innovative assets in its pipeline, with 26 currently in clinical trials.
The big picture
Akeso's inclusion in FirstWord Pharma's list signals growing recognition of Chinese pharmaceutical innovation on the global stage. The company's focus on bispecific antibodies and its 'IO 2.0+' strategy position it to capitalize on the evolving immuno-oncology market, but success hinges on navigating complex regulatory pathways and demonstrating clinical superiority against established therapies. This inclusion validates Akeso's strategy of global expansion and collaboration, but also highlights the inherent risks associated with drug development and commercialization.
What we're watching
- Regulatory Scrutiny
- Increased scrutiny from regulatory bodies in both China and international markets will be critical for ivonescimab's approval timeline and commercial success.
- Competitive Landscape
- The competitive landscape for immuno-oncology therapies remains intense, and Akeso must demonstrate ivonescimab's differentiated efficacy and safety profile to gain market share.
- IO 2.0+
- Akeso's stated focus on 'IO 2.0+' and expansion into autoimmune and neurological disorders will determine the breadth of its future pipeline and revenue streams beyond oncology.
Related topics